BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 31675993)

  • 1. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
    Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
    [No Abstract]   [Full Text] [Related]  

  • 3. Large-scale analysis of
    Croes L; Beyens M; Fransen E; Ibrahim J; Vanden Berghe W; Suls A; Peeters M; Pauwels P; Van Camp G; Op de Beeck K
    Clin Epigenetics; 2018; 10():51. PubMed ID: 29682089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
    Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors.
    Nesset KA; Perri AM; Mueller CR
    Epigenetics; 2014 Jun; 9(6):851-9. PubMed ID: 24622770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
    Nasif D; Campoy E; Laurito S; Branham R; Urrutia G; Roqué M; Branham MT
    Clin Epigenetics; 2018 Aug; 10(1):111. PubMed ID: 30139383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
    Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation of the glucocorticoid receptor gene promoter in the placenta is associated with blood pressure regulation in human pregnancy.
    Dwi Putra SE; Reichetzeder C; Meixner M; Liere K; Slowinski T; Hocher B
    J Hypertens; 2017 Nov; 35(11):2276-2286. PubMed ID: 28817493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
    Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
    BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
    Venkatesh T; Shetty A; Chakraborti S; Suresh PS
    J Cell Physiol; 2019 Feb; 234(2):1071-1079. PubMed ID: 30189107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation and hormone receptor status in breast cancer.
    Benevolenskaya EV; Islam AB; Ahsan H; Kibriya MG; Jasmine F; Wolff B; Al-Alem U; Wiley E; Kajdacsy-Balla A; Macias V; Rauscher GH
    Clin Epigenetics; 2016; 8():17. PubMed ID: 26884818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
    Pinto AE; André S; Pereira T; Nóbrega S; Soares J
    Ann Oncol; 2001 Apr; 12(4):525-33. PubMed ID: 11398888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
    Wang Y; Gong X; Zhang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
    Manjegowda MC; Gupta PS; Limaye AM
    Gene; 2017 May; 614():65-73. PubMed ID: 28286086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
    Li X; Zhang W; Song J; Zhang X; Ran L; He Y
    Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer.
    van Hoesel AQ; van de Velde CJ; Kuppen PJ; Putter H; de Kruijf EM; van Nes JG; Giuliano AE; Hoon DS
    Breast Cancer Res Treat; 2012 Feb; 131(3):859-69. PubMed ID: 21479925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.